Source pmlive.com:
Biogen’s new multiple sclerosis (MS) therapy should be available to NHS patients in England within three months after NICE reversed an earlier appraisal decision.
Source PMLIVE.com:
Biogen’s new multiple sclerosis (MS) therapy should be available to NHS patients in England within three months after NICE reversed an earlier appraisal decision.
The cost-effectiveness regulator has published a final determination on Zinbryta (daclizumab) giving the go-ahead for the drug to be used routinely for patients with the relapsing/remitting form of the disease if they have failed to respond to first-line treatment with Sanofi’s Lemtrada (alemtuzumab) or have rapidly evolving severe MS.
NICE turned down Zinbryta in draft guidance issued last October, criticising the analysis submitted by Biogen of the cost effectiveness of daclizumab compared with other disease-modifying treatments. It faced an immediate backlash from patient groups, including the MS Trust, which said it was “frustrating that, yet again, access to an effective new treatment will be further delayed by the NICE appraisal process”. Read on.
